Warning! GuruFocus detected
1 Severe warning sign
with INCY.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Incyte Corp
NAICS : 541714
SIC : 8731
ISIN : US45337C1027
Compare
Compare
Traded in other countries / regions
INCY.USA0J9P.UKINCY.MexicoICY.Germany1INCY.ItalyI1NC34.BrazilINCY.Austria IPO Date
2019-06-14Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 49.56 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.11 | |||||
| Interest Coverage | 44.38 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.57 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.4 | |||||
| 3-Year EBITDA Growth Rate | -11.9 | |||||
| 3-Year EPS without NRI Growth Rate | -37.4 | |||||
| 3-Year FCF Growth Rate | -24.2 | |||||
| 3-Year Book Growth Rate | 1.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 89.61 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.76 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 0.01 | |||||
| 14-Day RSI | 0.61 | |||||
| 6-1 Month Momentum % | 15.02 | |||||
| 12-1 Month Momentum % | 50.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.97 | |||||
| Quick Ratio | 1.94 | |||||
| Cash Ratio | 1.31 | |||||
| Days Inventory | 83.42 | |||||
| Days Sales Outstanding | 66.09 | |||||
| Days Payable | 186.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 4.4 | |||||
| Shareholder Yield % | 17.11 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.64 | |||||
| Operating Margin % | 2.39 | |||||
| Net Margin % | 0.77 | |||||
| FCF Margin % | 6.43 | |||||
| ROE % | 0.81 | |||||
| ROA % | 0.56 | |||||
| ROIC % | 0.37 | |||||
| 3-Year ROIIC % | -126.04 | |||||
| ROC (Joel Greenblatt) % | 40.86 | |||||
| ROCE % | 7.27 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 224.26 | |||||
| Forward PE Ratio | 11.98 | |||||
| PE Ratio without NRI | 45.87 | |||||
| Shiller PE Ratio | 62.65 | |||||
| Price-to-Owner-Earnings | 140.49 | |||||
| PS Ratio | 3 | |||||
| PB Ratio | 3.4 | |||||
| Price-to-Tangible-Book | 3.69 | |||||
| Price-to-Free-Cash-Flow | 47.16 | |||||
| Price-to-Operating-Cash-Flow | 34.5 | |||||
| EV-to-EBIT | 30.11 | |||||
| EV-to-Forward-EBIT | 7.8 | |||||
| EV-to-EBITDA | 23.53 | |||||
| EV-to-Forward-EBITDA | 7.37 | |||||
| EV-to-Revenue | 2.26 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | 40.84 | |||||
| Price-to-GF-Value | 0.77 | |||||
| Price-to-Projected-FCF | 1.56 | |||||
| Price-to-Median-PS-Value | 0.36 | |||||
| Price-to-Graham-Number | 2.74 | |||||
| Price-to-Net-Current-Asset-Value | 9.43 | |||||
| Price-to-Net-Cash | 72.95 | |||||
| Earnings Yield (Greenblatt) % | 3.32 | |||||
| FCF Yield % | 2.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Incyte Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 79,943.037 | ||
| EPS (TTM) (MXN) | 6.709 | ||
| Beta | 0.07 | ||
| 3-Year Sharpe Ratio | -0.19 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 20.39 | ||
| 14-Day RSI | 0.61 | ||
| 14-Day ATR (MXN) | 0.976739 | ||
| 20-Day SMA (MXN) | 1430.521 | ||
| 12-1 Month Momentum % | 50.71 | ||
| 52-Week Range (MXN) | 986 - 1486 | ||
| Shares Outstanding (Mil) | 193.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Incyte Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Incyte Corp Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Incyte Corp Frequently Asked Questions
What is Incyte Corp(MEX:INCY)'s stock price today?
The current price of MEX:INCY is MXN1430.49. The 52 week high of MEX:INCY is MXN1486.00 and 52 week low is MXN986.00.
When is next earnings date of Incyte Corp(MEX:INCY)?
The next earnings date of Incyte Corp(MEX:INCY) is 2025-04-30 Est..
Does Incyte Corp(MEX:INCY) pay dividends? If so, how much?
Incyte Corp(MEX:INCY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers